PDCD1 and cancer: MSI is a characteristic of a defective DNA mismatch repair process and tumours with high MSI levels are more susceptible to immune-enhancing therapies; in 2017 the FDA granted accelerated approval of pembrolizumab [16], a programmed cell death 1 (PD-1) inhibitor, for patients whose cancers have high MSI regardless of tumour type.